Summary:
This is a study that is primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/IV placebo in subjects with Relapsing MS.
Qualified Participants Must:
• Participants must be 18-55 years old and diagnosed with RMS
Qualified Participants May Receive:
Compensation for time and travel, may receive investigational medication or placebo